三结构域蛋白家族在肝细胞癌中的表达及意义

doi:10.3760/cma.j.issn.1673-422X.2018.06.014

摘要/Abstract

摘要： 三结构域蛋白（TRIM）家族是一个重要的蛋白家族，其在细胞生物学过程中具有多种功能，包括细胞内信号传导、细胞生长及凋亡、固有免疫、自噬和肿瘤发生等。许多研究证实TRIM在肝细胞癌中呈特异性表达，与肝细胞癌的发生、转移及预后密切相关。TRIM有望成为监测肝细胞癌发生发展的标志物，在早期诊断、治疗和预后判断等方面具有广阔前景。

关键词: 癌, 肝细胞, 三结构域家族

Abstract: Tripartite motif (TRIM) family, a very important protein family, has various functions in cellular biological processes including intracellular signal transduction, cell growth and apoptosis, innate immunity, autophagy and tumorigenesis. The specific expressions of TRIM in hepatocellular carcinoma are proved by many researches, which are closely related to the occurrence, metastasis and prognosis of hepatocellular carcinoma. TRIM are expected to be markers for the occurrence and development of hepatocellular carcinoma, and have broad prospects in the early diagnosis, therapy and prognosis of hepatocellular carcinoma.

Key words: Carcinoma, hepatocellular, Tripartite motif family

李蒙，贺德. 三结构域蛋白家族在肝细胞癌中的表达及意义[J]. 国际肿瘤学杂志, 2018, 45(6): 375-378.

Li Meng, He De. Expression and significance of tripartite motif family proteins in hepatocellular carcinom[J]. Journal of International Oncology, 2018, 45(6): 375-378.

参考文献

［1］ Hatakeyama S. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis［J］. Trends Biochem Sci, 2017, 42(4): 297-311. DOI: 10.1016/j.tibs.2017.01.002. ［2］ Esposito D, Koliopoulos MG, Rittinger K. Structural determinants of TRIM protein function［J］. Biochem Soc Trans, 2017, 45(1): 183-191. DOI: 10.1042/BST20160325. ［3］ Zhang Z, Xu C, Zhang X, et al. TRIM11 upregulation contributes to proliferation, invasion, and EMT of hepatocellular carcinoma cells［J］. Oncol Res, 2017, 25(5): 691-699. DOI: 10.3727/096504016X14774897404770. ［4］ Zhou Z, Liu Y, Ma M, et al. Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/βcatenin signaling pathway［J］. Biomed Pharmacother, 2017, 96: 98-103. DOI: 10.1016/j.biopha.2017.09.132. ［5］ Kang KJ, Ahn KS. Anatomical resection of hepatocellular carcinoma: a critical review of the procedure and its benefits on survival［J］. World J Gastroenterol, 2017, 23(7): 1139-1146. DOI: 10.3748/wjg.v23.i7.1139. ［6］ Erstad DJ, Tanabe KK. Hepatocellular carcinoma: earlystage management challenges［J］. J Hepatocell Carcinoma, 2017, 4: 81-92. DOI: 10.2147/JHC.S107370. ［7］ Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis［J］. J Carcinog, 2017, 16: 1. DOI: 10.4103/jcar.JCar_9_16. ［8］ Chao J, Zhang XF, Pan QZ, et al. Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma［J］. Med Oncol, 2014, 31(8): 102. DOI: 10.1007/s12032-014-0102-9. ［9］ Huang XQ, Zhang XF, Xia JH, et al. Tripartite motifcontaining 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer［J］. Chin J Cancer, 2017, 36(1): 77. DOI: 10.1186/s40880-017-0240-5. ［10］ Chen Y, Li L, Qian X, et al. High expression of TRIM11 correlates with poor prognosis in patients with hepatocellular carcinoma［J］. Clin Res Hepatol Gastroenterol, 2017, 41(2): 190-196. DOI: 10.1016/j.clinre.2016.09.010. ［11］ Li L, Dong L, Qu X, et al. Tripartite motif 16 inhibits hepatocellular carcinoma cell migration and invasion［J］. Int J Oncol, 2016, 48(4): 1639-1649. DOI: 10.3892/ijo.2016.3398. ［12］Ding Q, He D, He K, et al. Downregulation of TRIM21 contributes to hepatocellular carcinoma carcinogenesis and indicates poor prognosis of cancers［J］. Tumour Biol, 2015, 36(11): 8761-8772. DOI: 10.1007/s13277-015-3572-2. ［13］ Liu X, Huang Y, Yang D, et al. Overexpression of TRIM24 is associated with the onset and progress of human hepatocellular carcinoma［J］. PLoS One, 2014, 9(1): e85462. DOI: 10.1371/journal.pone.0085462. ［14］ Jiang S, Minter LC, Stratton SA, et al. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice［J］. J Hepatol, 2015, 62(2): 371-379. DOI: 10.1016/j.jhep.2014.09.026. ［15］ Wang Y, He D, Yang L, et al. TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis［J］. Biochem Biophys Res Commun, 2015, 463(3): 458-465. DOI: 10.1016/j.bbrc.2015.05.117. ［16］ Wang Y, Jiang J, Li Q, et al. KAP1 is overexpressed in hepatocellular carcinoma and its clinical significance［J］. Int J Clin Oncol, 2016, 21(5): 927-933. DOI: 10.1007/s10147016-0979-8. ［17］ Jin X, Pan Y, Wang L, et al. MAGETRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation［J］. Oncogenesis, 2017, 6(4): e312. DOI: 10.1038/oncsis.2017.21. ［18］ Cassano M, Offner S, Planet E, et al. Polyphenic trait promotes liver cancer in a model of epigenetic instability in mice［J］. Hepatology, 2017, 66(1): 235-251. DOI: 10.1002/hep.29182. ［19］ Guo P, Ma X, Zhao W, et al. TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex［J］. Oncogene, 2018, 37(4): 478488. DOI: 10.1038/onc.2017.349. ［20］ Liu J, Zhang C, Wang XL, et al. E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis［J］. Cell Death Differ, 2014, 21(11): 1792-1804. DOI: 10.1038/cdd.2014.121. ［21］ Cui X, Lin Z, Chen Y, et al. Upregulated TRIM32 correlates with enhanced cell proliferation and poor prognosis in hepatocellular carcinoma［J］. Mol Cell Biochem, 2016, 421(1-2): 127137. DOI: 10.1007/s11010-016-2793-z. ［22］ Chen Z, Lu X, Wang Z, et al. Coexpression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma［J］. Oncotarget, 2015, 6(4): 2538-2548. DOI: 10.18632/oncotarget.2991. ［23］ Chen Z, Wang Z, Guo W, et al. TRIM35 Interacts with pyruvate kinase isoform M2 to suppress the Warburg effect and tumorigenicity in hepatocellular carcinoma［J］. Oncogene, 2015, 34(30): 3946-3956. DOI: 10.1038/onc.2014.325. ［24］ Song L, Zhang W, Chang Z, et al. miR4417 targets tripartite motifcontaining 35 (TRIM35) and regulates pyruvate kinase muscle 2 (PKM2) phosphorylation to promote proliferation and suppress apoptosis in hepatocellular carcinoma cells［J］. Med Sci Monit, 2017, 23: 1741-1750. DOI: 10.12659/MSM.900296. ［25］ Jiang J, Yu C, Chen M, et al. Overexpression of TRIM37 promotes cell migration and metastasis in hepatocellular carcinoma by activating Wnt/betacatenin signaling［J］. Biochem Biophys Res Commun, 2015, 464(4): 1120-1127. DOI: 10.1016/j.bbrc.2015.07.089. ［26］ Zhu X, Wu Y, Miao X, et al. High expression of TRIM44 is associated with enhanced cell proliferation, migration, invasion, and resistance to doxorubicin in hepatocellular carcinoma［J］. Tumour Biol, 2016, 37(11): 14615-14628. DOI: 10.1007/s1327701653163. ［27］ Zhang Y, Wu SS, Chen XH, et al. Tripartite motif containing 52 (TRIM52) promotes cell proliferation in Hepatitis B virusassociated hepatocellular carcinoma［J］. Med Sci Monit, 2017, 23: 5202-5210. ［28］ Qiu X, Huang Y, Zhou Y, et al. Aberrant methylation of TRIM58 in hepatocellular carcinoma and its potential clinical implication［J］. Oncol Rep, 2016, 36(2): 811-818. DOI: 10.3892/or.2016.4871. ［29］ Yang YF, Zhang MF, Tian QH, et al. TRIM65 triggers βcatenin signaling via ubiquitylation of Axin1 to promote hepatocellular carcinoma［J］. J Cell Sci, 2017, 130(18): 3108-3115. DOI: 10.1242/jcs.206623.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[6]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[7]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[8]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[9]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[10]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[11]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[12]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[13]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[14]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[15]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.